Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report

BACKGROUND: Besides the clinical benefit of crizotinib in ALK-rearranged metastatic non-small cell lung cancer (NSCLC), concerns about its hepatotoxicity have arisen. It is not clear whether this is a drug class side effect or if the use of other selective ALKs inhibitors is safe after this serious...

Full description

Saved in:
Bibliographic Details
Published in:BMC Pulm Med
Main Authors: Duarte, Flávia Amaral, Rodrigues, Leonardo Brand, Paes, Flávia Rocha, Diniz, Paulo Henrique Costa, Lima, Helena Flávia Cuba de Almada
Format: Artigo
Language:Inglês
Published: BioMed Central 2021
Subjects:
Case Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841898/
https://ncbi.nlm.nih.gov/pubmed/33509141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-020-01390-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items